Danaher stock: TD Cowen raises target from USD 236.00 to USD 255.00

Danaher Corp. (ISIN US2358511028) has a fresh USD 255.00 price target from TD Cowen, up from USD 236.00, while the company enters its third-quarter reporting date with its second-quarter operating trends as the latest detailed baseline. Benzinga reported on October 19, 2026 that TD Cowen analyst Dan Brennan maintained a Buy rating and raised the target from USD 236.00 to USD 255.00 on October 13, 2026. Danaher stock was trading at EUR 204.75 at Lang & Schwarz on October 21, 2026 at 4:31 p.m. CEST.

Target rises ahead of results

The target increase puts TD Cowen's stated valuation above Danaher's primary-market share price of USD 229.93 as of October 21, 2026 at 10:34 a.m. ET. The target itself is 11.00 percent above that USD 229.93 price, using the same currency and date.

The analyst action came before Danaher's scheduled third-quarter results. Benzinga said on October 19, 2026 that the company was due to report before the opening bell on October 21, 2026, with consensus revenue of USD 6.56 billion and consensus earnings per share of USD 1.92.

Second-quarter growth remains mixed

Danaher reported USD 6.30 billion in second-quarter 2026 sales, while core revenue increased 3.00 percent year over year. Adjusted diluted earnings per share rose 8.00 percent to USD 1.94, according to the company's second-quarter earnings call transcript dated July 21, 2026. Yahoo Finance also reported an adjusted operating margin of 27.10 percent and free cash flow of USD 1.30 billion for the quarter.

The second-quarter picture was uneven across the portfolio. Core growth excluding respiratory testing revenue reached 4.50 percent, 150 basis points above the first-quarter pace, while the gross profit margin was 57.60 percent and the adjusted operating margin declined by 20 basis points year over year. Management raised full-year 2026 adjusted earnings-per-share guidance to USD 8.45-8.60 from USD 8.35-8.55 in the July call.

Valuation and trading frame

Danaher traded at a primary-market price of USD 229.93 on the NYSE at 10:34 a.m. ET on October 21, 2026. Its market capitalization was USD 161.6 billion, its price-to-earnings ratio was 37.64, and its 52-week range was USD 160.93 to USD 242.80 on the same date. The current USD price stood 5.30 percent below the 52-week high.

For comparison, Thermo Fisher Scientific traded at USD 694.69 on the NYSE at 10:34 a.m. ET on October 21, 2026, with a market capitalization of USD 256.9 billion and a price-to-earnings ratio of 36.67. IQVIA traded at USD 271.42 on the NYSE at 10:34 a.m. ET, with a market capitalization of USD 44.7 billion and a price-to-earnings ratio of 33.66.

What the target means for Danaher

The higher TD Cowen target reflects a more constructive view than the second-quarter margin trend alone would suggest. For investors, the key balance is between improving core demand and the continuing effect of respiratory testing comparisons on reported growth.

Stock price and outlook

The analyst target, second-quarter growth figures and the October 21 reporting date give Danaher stock three separate reference points for assessing the current valuation. The company operates across biotechnology, diagnostics and life sciences, with its portfolio focused on instruments, consumables, software and services used in research and healthcare.

The further course of trading is shown by the continuously updated real-time quote of Danaher stock.

Danaher stock facts

• Company: Danaher Corporation
• ISIN: US2358511028
• Ticker: DHR
• Primary exchange: NYSE
• Price Lang & Schwarz (as of October 21, 2026, 4:31 p.m. CEST): EUR 204.75
• Market capitalization: USD 161.6 billion (as of October 21, 2026)
• 52-week range: USD 160.93-242.80 (as of October 21, 2026)
• Sector / Industry: Healthcare / Medical - Diagnostics & Research

Market context: Market report S&P 500.

More news and analyses on Danaher stock